By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Merck said after the close the market yesterday that it has granted Laboratory Corporation of America a non-exclusive license to commercialize a genetic test to help predict patient response to peginterferon alpha-based therapy for hepatitis C virus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.